Bharat BiotechCOVAXINAnnouncement Bharat Biotech and ICMR Announce Interim Results from Phase 3 trials of #COVAXIN ®️; Demonstrates overall Interim Clinical Efficacy of 78% and 100% efficacy against Severe#COVID19 disease.
Covaxin effective against double mutant strain found in India: ICMR study
Rajasthan: 320 doses of COVAXIN missing from cold storage of Hari Bux Kanwatia Govt hospital, Jaipur. FIR registered. Nodal Officer of the vaccination centre here says, "There's systematic record of doses coming at centre. So it's suspected that vaccines went missing from store."
COVAXIN has demonstrated an interim vaccine efficacy of 81% in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR: Bharat Biotech
Covaxin has shown less than 10 % adverse reactions, while others have 60-70% adverse reactions.AstraZeneca was giving 4g paracetamol to volunteers to suppress such reactions. We haven’t given paracetamol to any volunteer. I can assure our vaccine is a 200 % safe:Bharat Biotech MD
The data from COVAXINPhase I & II clinical trials reveals that it not only produces neutralizing antibodies in all participants but also sensitises CD4 T lymphocytes that imparts durable immune response @BharatBiotechL @PMOIndiat @ICMRDELHI @icmr_niv @MoHFW_INDIA @DBTIndia
For those spreading rumours let it be known that EUA for COVAXIN is differently conditional – in clinical trial mode EUA for COVAXIN is different from COVISHIELD because its use will be in clinical trial mode. All COVAXIN recipients to be tracked,monitored as if they’re in trial
COVAXIN is more likely to work against newer variants like N501Y Variant (UK variant) & any other that may arise due to antigenic drift as it contains immunogens (epitopes) from other genes in addition to those from Spike protein Inactivated virus from NIV also had D614G mutation